We conducted a randomized controlled clinical trial comparing DFI and OS of 147 women with stage IIIB squamous cervical cancer who received either cisplatin plus RT ( CRT ) or RT alone ( 72 patients in the CRT group and 75 patients in the RT-only group ) .